Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 26, Number 12—December 2020

Trends in Population Dynamics of Escherichia coli Sequence Type 131, Calgary, Alberta, Canada, 2006–20161

Gisele Peirano2, Tarah Lynch2, Yasufumi Matsumara2, Diego Nobrega, Thomas J. Finn, Rebekah DeVinney, and Johann D.D. PitoutComments to Author 
Author affiliations: University of Calgary Cummings School of Medicine, Calgary, Alberta, Canada (G. Peirano, T. Lynch, T.J. Finn, R. De Vinney, J.D.D. Pitout); Alberta Precision Laboratories, Calgary (G. Peirano, T. Lynch, J.D.D. Pitout); Kyoto University Graduate School of Medicine, Kyoto, Japan (Y. Matsumara); University of Calgary, Calgary (D. Nobrega); University of Pretoria, Pretoria, South Africa (J.D.D. Pitout)

Main Article

Table 2

Incidence rates/100,000 residents for Escherichia coli sequence type 131 clades, Calgary, Alberta, Canada, 2006, 2012, and 2016*

Clade IR (95% CI)
2006 2012 2016
A 0.00a (0.00–0.34) 1.48b (0.88–2.34) 1.15b (0.66–1.87)
B 1.30 (0.71–2.18) 0.74 (0.34–1.41 0.65 (0.30–1.23)
C0 0.46a (0.15–1.08) 0.00b (0.00–0.30) 0.00b (0.00–0.26)
C1-nonM27 2.22a (1.55–3.60) 4.61b (3.48–5.99) 2.94a (2.11–3.99)
C1-M27 0.09a (0.00–0.56) 0.33 (0.09–0.84) 0.57b (0.25–1.13)
C2 0.83a (0.41–1.72) 5.19b (3.98–6.63) 4.81b (3.73–6.11)
Total 4.91a (3.68–6.42) 12.35b(10.45–14.49) 10.12b (8.52–11.94)

*Rates followed by different superscript letters indicate significant differences between years at the 5% level. IR; incidence rate.

Main Article

1Accepted as an oral presentation for the 30th European Congress of Clinical Microbiology and Infectious Diseases, Paris, France, April 18–21, 2020.

2These authors contributed equally to this article.

Page created: August 05, 2020
Page updated: November 19, 2020
Page reviewed: November 19, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.